SUSAR stands for Suspected Unexpected Serious Adverse Reaction. It refers to an adverse event that occurs during a clinical trial which is both serious and unexpected, and is suspected to be related to the study drug or intervention.
SUSARs are a critical component of drug safety monitoring in clinical research. They require prompt reporting to regulatory authorities and ethics committees, as they may impact the overall safety profile of the investigational product and the conduct of the clinical trial.
SUSARs play a crucial role in ensuring patient safety and maintaining the integrity of clinical trials. They serve as early warning signals for potential serious risks associated with investigational products, allowing researchers and regulatory bodies to take swift action to protect study participants and reassess the risk-benefit profile of the study.
The identification and reporting of SUSARs are essential for compliance with regulatory requirements and ethical standards in clinical research. Proper management of SUSARs contributes to the overall quality and reliability of clinical trial data, ultimately influencing decisions about drug development, approval, and post-marketing surveillance.
We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…
The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…
The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…
Copyright @ 2025 Axcellant